Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 8 publications
(6 reference statements)
0
2
0
Order By: Relevance
“…The diagnosis of ON was based on the criteria described by the Optic Neuritis Treatment Trial [ 31 , 32 ]. The inclusion and exclusion criteria followed our previous study [ 30 ], but with no restriction on the times of attacks, initial visual acuity (VA), the disease duration, or the presentation of a related demyelinating disease of the CNS, such as transverse myelitis (TM), area postrema syndrome, acute disseminated encephalomyelitis, or MS.…”
Section: Methodsmentioning
confidence: 99%
“…The diagnosis of ON was based on the criteria described by the Optic Neuritis Treatment Trial [ 31 , 32 ]. The inclusion and exclusion criteria followed our previous study [ 30 ], but with no restriction on the times of attacks, initial visual acuity (VA), the disease duration, or the presentation of a related demyelinating disease of the CNS, such as transverse myelitis (TM), area postrema syndrome, acute disseminated encephalomyelitis, or MS.…”
Section: Methodsmentioning
confidence: 99%
“…ON was diagnosed in accordance with the criteria described by the Optic Neuritis Treatment Trial. 20,21 The inclusion criteria for the subjects in this study were as follows: (1) first attack of acute vision loss in one or both eyes with or without ocular pain; (2) no presentation of neurological disability other than visual impairment at the onset; (3) severe visual loss defined as best corrected VA (BCVA; Snellen) worse than 20/200 at the onset; (4) consistent visual field defect; (5) presence of relative afferent pupillary defect or visual evoked potential abnormalities; (6) presence of optic disc oedema; (7) detection of demyelinating lesions at the optic nerve with enhancement on T1-weighted orbit magnetic resonance imaging (MRI); (8) administration of IVMP treatment at 1000 mg/day for 3-5 days after onset and no other treatment; (9) no obvious visual improvement of more than three lines of VA after IVMP treatment; (10) disease duration from onset to PE treatment less than 60 days; (11) tolerance for and completion of the course of five-cycle PE treatment without serious adverse events. Only patients who met all of the inclusion criteria were included.…”
Section: Study Subjectsmentioning
confidence: 99%